• In March 2026, Pulse Biosciences, Inc. announced a new focus on accelerating development and future commercialization of its nPulse Cardiac Catheter Ablation System after reporting European feasibility data in Atrial Fibrillation showing high procedural success, durable Pulmonary Vein Isolation, efficient procedure times, and a low rate of serious adverse events.
• This shift in capital allocation toward the electrophysiology program, alongside streamlined spending in surgical and soft-tissue ablation and upcoming late-breaking data at Heart Rhythm 2026, marks a meaningful refocus of the company’s nanosecond pulse field ablation platform on the cardiac catheter opportunity.
• Next, we’ll examine how concentrating resources on the nPulse Cardiac Catheter’s promising AFib data could reshape Pulse Biosciences’ broader investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 25 companies in the world exploring or producing it. Find the list for free.

Pulse Biosciences Investment Narrative Recap

To own Pulse Biosciences today, you have to believe its nanosecond PFA platform can carve out a meaningful role in atrial fibrillation and thyroid care, despite minimal current revenue and sizable losses. The latest nPulse Cardiac Catheter data and capital shift increase the odds that the next major catalyst is the pivotal IDE launch and AF regulatory path, while also concentrating risk around clinical, regulatory and competitive outcomes in the electrophysiology business.

The most relevant recent update alongside this AF announcement is the durable thyroid nodule data from Vybrance, showing strong volume reduction and high patient satisfaction with no serious adverse events. That real world thyroid experience is now positioned as a supporting pillar rather than the main growth engine, which may matter if catheter timelines, reimbursement decisions or electrophysiology adoption do not progress as investors expect.

Yet beneath the impressive AFib data, investors should still be aware that...

Pulse Biosciences' narrative projects $29.7 million revenue and $3.9 million earnings by 2028. This requires 601.5% yearly revenue growth and a $78.6 million earnings increase from $-74.7 million today.

Uncover how Pulse Biosciences' forecasts yield a $22.00 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Before this AF update, the most optimistic analysts were already assuming revenue could grow about 690 percent annually and reach US$42.3 million by 2029, so if you are weighing that bullish view against the concentrated electrophysiology risk, it is worth recognizing how far expectations diverge and how this new data could shift both narratives in different directions.

Explore 2 other fair value estimates on Pulse Biosciences - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pulse Biosciences research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Pulse Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pulse Biosciences' overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.